- Home
- WASH vs RIGL Comparison
WASH vs RIGL Comparison
Compare WASH & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WASH | RIGL |
|---|---|---|
| Founded | 1800 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 682.2M | 628.4M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WASH | RIGL |
|---|---|---|
| Price | $33.46 | $27.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $30.25 | ★ $45.67 |
| AVG Volume (30 Days) | 165.2K | ★ 350.7K |
| Earning Date | 04-20-2026 | 03-03-2026 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | 266.26 | ★ 1867.68 |
| EPS | 2.71 | ★ 19.48 |
| Revenue | $229,048,000.00 | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.19 | $12.75 |
| P/E Ratio | $12.14 | ★ $1.32 |
| Revenue Growth | ★ 127.57 | 64.15 |
| 52 Week Low | $24.97 | $15.50 |
| 52 Week High | $37.08 | $52.24 |
Technical Indicators
Market Signals| Indicator | WASH | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 40.41 |
| Support Level | $28.26 | $26.38 |
| Resistance Level | $37.08 | $30.59 |
| Average True Range (ATR) | 0.77 | 0.96 |
| MACD | 0.10 | 0.33 |
| Stochastic Oscillator | 91.04 | 84.11 |
Price Performance
Historical ComparisonAbout WASH Washington Trust Bancorp Inc.
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, and wealth management and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.